Skip to main content

Table 2 Baseline participant demographics and clinical characteristics

From: Health-related quality of life in patients with inoperable malignant bowel obstruction: secondary outcome from a double-blind, parallel, placebo-controlled randomised trial of octreotide

Characteristic Octreotide
N = 52
Placebo
N = 54
Age in years, mean (SD) 62.9 (13.6) 66.3 (12.2)
Gender, female, n (%) 47 (90.4) 38 (70.4)
Performance status (AKPS), median (IQR) 50 (40–60) 50 (40–60)
BPI pain score, median (IQR) 3 (1–5) 4 (1.25–5)
Nauseaa, median (IQR) 2 (1–2) 1(1–2)
Level of bowel obstruction
 Gastric outlet/duodenal, n (%) 5 (9.6) 9 (16.7)
 Small bowel/ multi-level, n (%) 34 (65.4) 34 (63.0)
 Large bowel, n (%) 2 (3.9) 3 (5.6)
 Indeterminate, n (%) 11 (21.2) 8 (14.8)
EORTC QLQ-C15-Pal overall quality of life score, mean (SD) 22.1 (24.3) 31.5 (27.2)
  1. AKPS Australia-modified Karnofsky Performance Status scale, scores range from 0 to 100 where a higher score indicates better performance in terms of work, activity and self-care, BPI Brief Pain Inventory, scores range from 0 to 10 where higher score represents more pain, EORTC QLQ-C15-Pal The European Organization for Research and Treatment of Cancer quality of life palliative care questionnaire, scores range from 0 to 100 and higher scores represent better QOL, IQR Inter-quartile range, SD Standard deviation
  2. anausea numerical rating scale ranges from 0 to 5, where a higher score indicates more nausea
\